Myleran (Busulfan) News and Research

RSS

GlaxoSmithKline to acquire 16% shareholding in Aspen Pharmacare

GlaxoSmithKline plc (GSK) today announced that it has agreed to extend its strategic relationship with Aspen Pharmacare Holdings Limited (Aspen) and to acquire a 16% shareholding in the South African based pharmaceuticals company.

12 May 2009

Adult stem cells may be beneficial for certain cardiovascular disorders and autoimmune diseases

A review of previously published research suggests that stem cells harvested from an adult's blood or marrow may provide treatment benefit to select patients for some autoimmune diseases and cardiovascular disorders, according to an article in the February 27 issue of JAMA: The Journal of the American Medical Association.

27 Feb 2008

Nanoparticle encapsulation improves bioavailability of leukemia drug

Busulfan, which belongs to a family of drugs known as alkylating agents, is used to treat hematological malignancies, including chronic myelogenous leukemia.

9 Oct 2006

Circulating bone-marrow derived cells do not contribute to egg formation

Ovulated egg cells, or oocytes, in adult female mice are not formed from germ cells in the blood or bone marrow.

14 Jun 2006

Novel way of administering an anti-cancer drug to bone-marrow transplant patients using continuous infusion

The new method achieves more predictable, stable drug levels in patients than the current method and could eventually allow doctors to more accurately adjust doses to accommodate individual differences in metabolism, thus increasing treatment effectiveness while avoiding side effects, said University of North Carolina at Chapel Hill researchers.

20 May 2005

Single dose phase I data on CG53135 for the prevention of oral mucositis

CuraGen Corporation has announced results presented from a Phase I clinical trial with CG53135 for the prevention of oral mucositis (OM) in patients receiving high dose chemotherapy (HDCT) followed by autologous hematopoietic stem cell transplantation (AHSCT) at the ASH 46th Annual Meeting in San Diego, CA.

5 Dec 2004

Data suggests potential role of Quadramet in conjunction with chemotherapy for the treatment of acute myeloid leukemia

Cytogen Corporation today announced the presentation of new data relating to its lead therapeutic product Quadramet (samarium Sm-153 lexidronam injection) during the 36th Congress of the International Society of Pediatric Oncology (SIOP).

20 Sep 2004